STAT - Reporting from the frontiers of health and medicine

Biotech

Health

First Opinion

By Jennifer Gunter

Biotech ‘We have a tragedy of the commons’: How a VC thinks his new company can lower drug prices
In the Lab Tweaking how CAR-T therapy kills tumors could stop a dangerous side effect, study finds
First Opinion Microglia: a new target in the brain for depression, Alzheimer’s, and more?
Adam's Take The truth about JPM: Less is more
Politics Airing frustrations with pharma, a Republican FTC commissioner just endorsed Medicare negotiation

Daily, market-moving coverage of biotech and pharma

Inside intelligence on the NIH, the FDA, and Congress

Profiles of the power players shaping the industry

Analysis of the latest scientific developments

How swallowing a star might keep you from missing a dose of medicine
Lilly exec says ‘there are no villains’ in the high-priced insulin market
Pharmalittle: FTC member favors Medicare negotiation on drug prices; BioMarin weighs pricing world’s most expensive drug

Health

Health

Health

Health

Don't Miss

By STAT

Special Report

First Opinion Why Black doctors like me are leaving faculty positions in academic medical centers
First Opinion Goop’s pseudoscience ministry comes to Netflix
Biotech A ‘radical proposition’: A health care veteran tries to upend the system and bring drug prices down
Health ‘How long do I have?’ A website on cancer survival rates, from the co-founder of GoodRx, seeks to provide clarity
Business A ‘Shark Tank’-funded test for food sensitivity is medically dubious, experts say